Target intelligence / Profile preview

Secretion associated Ras related GTPase 1A (SAR1A)

Target
SAR1A
Molecular classification
Small GTPase, Enzyme, COPII vesicle coat protein
01

Overview

Secretion associated Ras related GTPase 1A (SAR1A) is a small GTPase essential for the formation of COPII-coated vesicles which mediate the transport of proteins from the endoplasmic reticulum to the Golgi apparatus[1][2][3][4]. SAR1A switches between an inactive GDP-bound and active GTP-bound state, recruiting the COPII coat to the ER membrane and driving vesicle formation and cargo selection[1][2]. It also functions as a leucine sensor regulating TORC1 signaling and cellular metabolism, a property independent of its GTPase activity[1]. SAR1A is critical for cell viability—as demonstrated by embryonic lethality upon knockout in mice—and shows functional overlap with its paralog SAR1B; upregulation of SAR1A can compensate for SAR1B deficiency, suggesting therapeutic potential in rare lipid transport disorders[3][4]. No human disease has been directly attributed to SAR1A mutation, but its perturbation would severely disrupt protein secretion. No clinically approved drugs target SAR1A, nor are there known biomarkers or safety profiles for therapeutic modulation.

Other names
SAR1SARASaraSARA1COPII-associated small GTPaseSmall COPII coat GTPase SAR1AGTP-binding protein SAR1aSAR1 gene homolog ASAR1 homolog ASAR1a gene homolog 1masra2
02

Mechanism of action

Experimental: gene expression upregulation to compensate for SAR1B deficiency, thereby restoring normal vesicle trafficking and lipid secretion

03

Biological functions

Vesicle budding from the ERCOPII-coated vesicle assemblyEndoplasmic reticulum to Golgi transportProtein cargo sortingLeucine sensor for TORC1 signalingRegulation of cellular metabolism, growth, survival
04

Disease associations

Chylomicron retention disease (through functional redundancy/compensation with SAR1B)Craniolenticulosutural dysplasiaOther disorders linked to vesicle trafficking, though a human disease directly caused by SAR1A mutation has not been described
05

Safety considerations

Manipulation may affect essential ER-to-Golgi transport; deficiency in SAR1A is embryonic lethal in miceNo safety data for pharmacologic targeting; possible risks of broad cellular disruption if inhibited or overexpressed
06

Interacting drugs

None currently approved or validated; experimental upregulation of SAR1A (e.g., via gene therapy approaches) has been suggested as a potential strategy to compensate for SAR1B deficiency in chylomicron retention disease
07

Biomarkers

No validated clinical biomarkers for SAR1A in patient selection or efficacy monitoring

Beyond the preview

Go deeper on Secretion associated Ras related GTPase 1A (SAR1A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Secretion associated Ras related GTPase 1A (SAR1A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call